Connection
Kimi Kondo to Imatinib Mesylate
This is a "connection" page, showing publications Kimi Kondo has written about Imatinib Mesylate.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.024 |
|
|
|
-
Jelinek J, Gharibyan V, Estecio MR, Kondo K, He R, Chung W, Lu Y, Zhang N, Liang S, Kantarjian HM, Cortes JE, Issa JP. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One. 2011; 6(7):e22110.
Score: 0.024